← Evidence map

ArticleApplied biochemistry and biotechnology2026

Engineering and Partial Characterization of an Anti-IL-23/Anti-TNF-α Bispecific Domain Antibody Fused to Human Serum Albumin Domain for Inflammatory Disease Therapy.

Sandeep et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Engineering and Partial Characterization of an Anti-IL-23/Anti-TNF-α Bispecific Domain Antibody Fused to Human Serum Albumin Domain for Inflammatory Disease Therapy. | OpenQuestion